Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sage Therapeutics, Inc. - Common Stock (NQ: SAGE )

7.850 +0.160 (+2.08%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sage Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Starbucks, Sage, Outset Medical, and Super Micro and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
SAGE Class Action Alert: Robbins LLP Reminds Stockholders of the Sage Therapeutics, Inc. Class Action
From Robbins LLP
Via GlobeNewswire
SAGE SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Expert Outlook: Sage Therapeutics Through The Eyes Of 14 Analysts
Via Benzinga
Analyst Expectations For Sage Therapeutics's Future
Via Benzinga
19 Analysts Have This To Say About Sage Therapeutics
Via Benzinga
SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
SAGE THERAPEUTICS, INC. (NASDAQ: SAGE) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Sage Therapeutics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
REMINDER – Sage Therapeutics, Inc. Investor Alert: Robbins LLP Reminds Shareholders of the SAGE Class Action Lawsuit
From Robbins LLP
Via Business Wire
SAGE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Sage Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Rosen Law Firm Urges Sage Therapeutics, Inc. (NASDAQ: SAGE) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
SAGE INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
SAGE THERAPEUTICS, INC. (NASDAQ: SAGE) INVESTOR ALERT: Investors With Large Losses in Sage Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
From Bernstein Liebhard LLP
Via GlobeNewswire
Stockholder Notice: Robbins LLP Informs Stockholders of the Class Action Filed Against Sage Therapeutics, Inc.
From Robbins LLP
Via GlobeNewswire
SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Sage Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Sage, Biogen Shelve Development Of Nervous System Disorder Drug After Data Disappoints
Sage Therapeutics and Biogen will end further development of SAGE-324 in ET, focusing instead on evaluating future steps. 
Via Benzinga
Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails
The companies are no longer developing their drug for essential tremor treatment. 
Via Investor's Business Daily
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to dive into the biggest pre-market stock movers for Wednesday as we check out all of the hottest news to start the day with! 
Via InvestorPlace
Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor
From Sage Therapeutics, Inc.
Via Business Wire
Netflix To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Sage Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024
From Sage Therapeutics, Inc.
Via Business Wire
Delta Air Lines Posts Downbeat Earnings, Joins United Airlines, American Airlines And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Mama's Creations, GameStop And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Sage Therapeutics Reports Phase 2 Huntington's Data
On Tuesday before the market opened, Sage Therapeutics announced findings regarding Huntington's Disease (HD) based upon topline results from the Phase 2 SURVEYOR Study. 
Via Benzinga
Sage Therapeutics Announces Phase 2 SURVEYOR Study Reinforces Cognitive Impact of Huntington’s Disease
From Sage Therapeutics
Via Business Wire
Sage Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
From Sage Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS